36 results about "Immunomodulin" patented technology

This application relates to trans amplifying RNAs encoding immune modulating proteins, and methods of use thereof for payload expression in cells and subjects.

Provided herein are methods of treatment and uses involving an immunomodulatory TACI-Fc fusion protein that exhibits neutralizing activity of BAFF and APRIL (or BAFF / APRIL heterotrimers). The provided TACI-Fc protein may include variant domains of Transmembrane Activator and CAML Interactor (TACI). The methods and uses provide therapeutic utility for a variety of immunological diseases, disorders or conditions, such as B cell-mediated diseases, disorder or conditions.

The invention belongs to the technical field of biological medicine, and particularly discloses application of CCL28 as a biomarker and a therapeutic target in sepsis. The invention particularly relates to application of a CCL28 gene or a detection reagent for the expression quantity of the CCL28 gene in preparation of a kit for diagnosis or prognosis monitoring of sepsis. The expression of the novel immunomodulatory factor CCL28 in a sepsis patient is obviously improved, and the expression level of the novel immunomodulatory factor CCL28 is in obvious negative correlation with poor prognosis of sepsis. Through CLP induction of a sepsis mouse model, the invention finds that the expression level of CCL28 in sepsis mouse blood, abdominal cavity lavage fluid (PLF), liver and kidney is significantly increased. By adopting the recombinant CCL28 for treatment, the bacterial load in the mice with sepsis can be remarkably reduced, and the multi-organ injury of the mice with sepsis can be reduced, so that the survival rate of the mice with sepsis can be remarkably improved. In conclusion, the invention explores a novel immunomodulatory protein CCL28, and the novel immunomodulatory protein CCL28 not only can be used as a diagnosis and prognosis biomarker of sepsis, but also can be used as a novel target spot for treating sepsis.

Provided are vaccines and immunomodulatory compositions containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo, that includes antigens and / or immunomodulatory proteins, nucleic acids, and nucleic acid encoding the proteins. The MEVs are formulated and administered by a variety of routes of administration that are advantageous for modulating the immune systems. Vaccines include those that are therapeutic for treating a disease, disorder, or condition, those that elicit an immunoprotective response, and / or otherwise modulate the immune system. The compositions include MEVs containing cargos for modulating intracellular receptors.

The invention discloses an immunomodulatory protein as well as a fusion protein, a preparation method and application thereof. The amino acid sequence of the immunomodulatory protein has at least 96% identity as compared with the amino acid sequence shown in SEQ ID NO: 1, and the amino acid residue difference at one or more sites of K46, S56, Y83 and K89 is included as compared with the amino acid sequence shown in SEQ ID NO: 1. Compared with the immunomodulatory protein in the prior art, the immunomodulatory protein provided by the invention has higher anti-tumor activity.

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

This invention relates to the finding that testis development related protein (TDRP; also termed Immunomoodulin or Imood herein) is a circulatory anxiogenic factor that modulates anxiety-like behaviour in mammalian models through the regulation of the immune system. Methods of treatment of mental disorders, such as anxiety, and TDRP antagonists for use in such methods are provided. Methods of diagnosing or monitoring a mental disorder in an individual by determining levels of TDRP in a sample and methods of screening for compounds that reduce levels of TDRP are provided.

This invention relates to APRIL and BAFF inhibitory immunomodulatory proteins and methods of using them, specifically providing immunomodulatory proteins exhibiting neutralizing activity against BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of transmembrane activators and CAML interactors (TACI). The provided immunomodulatory proteins include TACI-Fc fusion proteins. Nucleic acid molecules encoding said immunomodulatory proteins are also provided. The immunomodulatory proteins provide therapeutic efficacy against a variety of immune diseases, disorders, or conditions. Compositions and methods for preparing and using such proteins are also provided.

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract 20 26 21 41 08 10 A ug 2 02 6 A b s t r a c t 2 0 2 6 2 1 4 1 0 8 1 0 A u g 2 0 2 6

The present application relates to CTLA-4 variant immunomodulatory proteins and uses thereof. Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for the treatment of autoimmune or inflammatory conditions. Compositions and methods of making and using such proteins are provided.

To provide CTLA-4 variant immunomodulatory proteins and uses thereof.SOLUTION: The disclosure provides variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.SELECTED DRAWING: Figure 2

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. 20 24 20 45 59 01 J ul 2 02 4 2 0 2 4 2 0 4 5 5 9 0 1 J u l 2 0 2 4

The invention provides a neural stem cell exosome, the surface of the exosome is modified with liver targeting molecules and immunomodulatory proteins, the average particle size of the exosome is 40-200 nanometers, and the Zeta potential is-30 to-10 millivolts. Liver targeting molecules and immunomodulatory protein CD47 are co-modified on the surface of the exosome, and a mild membrane insertion method is adopted, so that the two technical problems of insufficient liver targeting and short in-vivo circulation time of the exosome are solved at the same time, and the treatment effect of the neural stem cell exosome as a liver drug delivery carrier is improved.

The invention provides a method of producing a non-immunogenic (bio)engineered tissue from pluripotent stem cells or pluripotent stem cell derivatives, the respective cells being deficient of MHC class I molecules and comprising an immunomodulatory protein on their surface, wherein the method comprises inducing the differentiation of the pluripotent stem cells into a cell type that is essential for the function of the engineered tissue under conditions that also allow the formation of the engineered tissue, thereby rendering the engineered tissue to be non-immunogenic to a recipient of the engineered tissue. The present invention further relates to an engineered tissue, a pharmaceutical composition comprising the engineered tissue, medical treatments using the engineered tissue and uses of the engineered tissue.

The invention discloses application of ganoderma lucidum immunomodulatory protein in preparation of a product for targeting TK1, and belongs to the technical field of biological medicine. The protein can be directly combined with a tumor proliferation marker TK1, and the expression level of TK1 is reduced, so that tumor cell proliferation is inhibited. The invention discloses a molecular mechanism that ganoderma lucidum immunomodulatory protein plays an anti-tumor role through targeting TK1 for the first time, and specifically discloses an amino acid site of the ganoderma lucidum immunomodulatory protein interacting with TK1. Based on the discovery, the invention also provides food, health-care food or medicine which contains the ganoderma lucidum immunomodulatory protein and is used for inhibiting TK1 or tumors, and the food, health-care food or medicine is particularly suitable for preventing and treating breast cancer. The invention provides a new direction for clinical application transformation of the ganoderma lucidum immunomodulatory protein, and has important development value and application prospect.

This application relates to trans amplifying RNAs encoding immune modulating proteins, and methods of use thereof for payload expression in cells and subjects.

The present invention relates to a recombinant protein, which comprises a spacer peptide and a recombinant Ganoderma lucidum immunomodulatory protein variant (rLZ-8 variant), wherein the amino acid sequence of the rLZ-8 variant comprises at least one amino acid mutation compared with the amino acid sequence shown in SEQ ID NO: 10. The present invention also relates to the application of the recombinant protein in the treatment of diseases.

To provide immunomodulatory proteins that provide therapeutic utility for a variety of immunological and oncological conditions.SOLUTION: There are provided immunomodulatory proteins that exhibit altered binding affinities to binding partners that are immune protein ligands involved in immunological responses, comprising at least one affinity modified non-immunoglobulin IgSF domain comprising one or more amino acid substitution(s) in a wild-type immunoglobulin superfamily (IgSF) domain.SELECTED DRAWING: Figure 1A

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.